The effect of pre-or posttreatment with glucan, a reticuloendothelial stimulant, on the course of Leishmania donovani infection was assessed in highly susceptible hamsters. Intravenous administration of glucan before or after L. donol'ani infection significantly suppressed proliferation of amastigote-stage parasites in liver and spleen. Glucan-activated peritoneal macrophages in vitro also significantly reduced multiplication of the intracellular parasite. Ultrastructural studies revealed a well-defined hepatic granulomatous response to glucan, with hypertrophic Kupffer cells and reduced numbers of intracellular parasites compared to the control group. In additional studies, groups of hamsters were immunized by intravenous injections of glucan with Formalin-killed promastigote-stage L. donovani cells and challenged 60 days after the last immunizing injection. This treatment regimen significantly prolonged the mean survival time of those hamsters which died after infection, relative to untreated control groups. Hamsters stimulated with the glucan-killed promastigote preparation also exhibited significant reductions in splenic amastigotes on days 10 and 21 postinfection compared with all other control groups, but on day 35, splenic amastigotes did not differ significantly from those of control animals. Our composite observations provide evidence for glucan-enhanced visceral leishmaniasis. nonspecific resistance of hamsters to
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Recent studies in our laboratories demonstrated that glucan, a ,B(1->3) glucopyranose derivative from the cell wall of yeast, has significant value as an immunopotentiator in enhancing both nonspecific and specific resistance of mice to infection with L. donovani (3, 13) . Glucan administered alone, either pre-or posttreatment, protected mice against infection with the protozoan, as measured by significantly reduced parasite burdens in organs (3) . Importantly, glucan also had an adjuvant effect when inoculated simultaneously with Formalin-killed promastigote-stage parasites (13) . Mice immunized with glucan and dead parasites exhibited significant resistance to a challenge infection delivered up to 80 days after stimulation. Injections of glucan alone provided a lesser degree of protection, but mice receiving dead parasites alone were not protected (13) .
Mice, however, respond spontaneously against L. donovani infection, and immunoprophylaxis could, therefore, be easier to achieve in the murine host than in more susceptible animal models. Hamsters are relatively unique in that they exhibit a poor immunological response to L. donovani and usually succumb to the infection even after inoculation with low numbers of parasites (26) . The hamster infection also resembles human kala-azar in that both may terminate fatally without chemotherapeutic intervention (19, 25, 31) . In the present study we evaluated the effect of pre-or posttreatment with glucan on the course of L. donovani infection in highly susceptible hamsters. Specifically, organ parasite counts (i.e., liver and spleen) were monitored during the course of the infection. The characteristics of the hepatic infection in glucantreated and control hamsters were further assessed by light and ultrastructural examination. In parallel studies, the ability of glucan-activated peritoneal macrophages from hamsters to suppress intracellular proliferation of the parasite was evaluated. Additionally, in a separate study, groups of hamsters were immunized with glucan and Formalin-killed promastigote-stage L. donovani cells. After challenge with viable parasites, changes in organ parasite counts and mortality were assessed.
MATERIALS AND METHODS
Parasite and experimental host. L. donov'ani 2S (27) was kindly provided by J. P. Farrell Hamsters were challenged by intravenous injection of 2.5 X 107 promastigotes. At designated intervals after injection, at least five hamsters in each treatment group were killed with chloroform vapor. Body, spleen, and liver weights were recorded, and impression slides were made from liver and spleen tissue. Slides were fixed with methanol, stained with Giemsa, and the parasite burdens in organs were estimated by the method of Stauber (25) .
For immunization, log-phase promastigotes were washed three times in EBSS and killed by suspension in 0.1% Formalin for 30 min at room temperature; they were kept overnight at 4°C. Parasites were then washed three times, counted in a hemacytometer, and suspended to the desired concentration in EBSS. A sample of each promastigote preparation was inoculated into culture medium, held at 25°C, and examined for at least 21 
RESULTS
Effects of pre-and posttreatment with glucan. Groups injected with promastigotes exhibited no significant difference in hepatic parasite burdens at 1 h after challenge (Table 1) . By days 8 and 16, postinfection hepatic parasite counts increased (P < 0.01) in hamsters receiving dextrose and in untreated animals. Total amastigote burdens in the liver continued to increase in the dextrosetreated group (P < 0.05) on day 30. The glucan pretreatment regimen significantly suppressed ' Hamsters were challenged (day 0) with 25.0 x 106 promastigotes intravenously. In the pretreatment group. glucan (3 mg) was injected on days 4, 7, 10, and 13 before challenge inocula. In the posttreatment group. glucan (3 mg) was injected on days 2. 6. and 10 after challenge inocula. The 5% dextrose group was injected as a pretreatment regimen. 6 Values are expressed as the mean ± standard error of the mean (N = 5 to 7 per group).
Significant value (P < 0.05) versus that for the 5% dextrose or untreated group.
"Significant value (P < 0.05) versus that for the untreated group.
hepatic parasite counts on day 8 (P < 0.05), day 16 (P < 0.005), and day 30 (P < 0.01) relative to both dextrose-treated control animals and untreated control animals. Similarly, the glucan postinfection treatment reduced hepatic parasite burdens on day 16 (P < 0.005) and day 30 (P < 0.01).
Although parasites in spleen tissue were too few to count at 1 h, proliferation of parasites was also noted in the spleen of untreated and dextrose-treated control groups on days 8, 16, and 30 postinfection (Table 2 ). These counts were compared with lesser splenic parasite counts (P < 0.05) in the glucan pretreatment group on days 16 and 30. The posttreatment glucan regimen, however, did not significantly reduce splenic parasite counts during the same time intervals.
At the initiation of challenge with promastigotes (day 4 after the last glucan injection) there was no significant difference in spleen weight, liver weight, or body weight ratios relative to control groups. Liver/body weight ratios remained unchanged throughout the course of the study. A significant parasite-induced splenomegaly, however, was evident in all groups as Ultrastructural studies. Each photomicrograph ( Fig. 1 and 2) was from a representative sample of tissue from hamsters in the dextrosetreated control group or the glucan pretreatment group on day 16 after intravenous inoculation with 2.5 x 107 promastigotes. The group injected with the viable parasite after glucan pretreatment ( Fig. 1) and the group injected with the parasite and dextrose (Fig. 2) both developed granulomas in the liver. The macrophages in the infected glucan-treated hamsters appeared to be activated and contained numerous glucan vacuoles and an occasional parasite (Fig. 1) . It was not difficult to locate macrophages containing glucan vacuoles in the livers of glucan-parasiteinjected animals. Macrophages containing parasites however, occurred with low frequency in the glucan-treated group. The number of parasites seen in any glucan-stimulated liver macrophage was never more than three.
Macrophages in the parasite-infected control animals also appeared to be activated: they contained well-developed arrays of rough endoplasmic reticulum and were frequently engorged with parasites (Fig. 2) . As many as nine profiles of L. donovani were seen within single macrophages in ultrathin sections of liver from parasite-infected control animals.
In vitro macrophage-L. donovani interaction. (Table 3) . At 24 hours, however, only 14.5 ± 3.1% of cells from glucan-treated animals were infected as compared to 53.9 ± 6.5% of cells from control animals (P < 0.001); the mean number of parasites per cell was 1.4 ± 0.1 and 2.0 ± 0.1 (P < 0.001) for those groups, respectively. On day 3 postinoculation, the percentage of infected cells was 31.8 ± 8.3% with 1.5 ± 0.1 parasites per cell for cells from the glucantreated group, as opposed to 79.0 ± 5.3% with 3.42 ± 0.6 parasites per cell for cells from the control group (P < 0.001).
Glucan-dead parasite immunization against L. donovani. To test the effectiveness of glucan as an adjuvant, studies were conducted in which hamsters were inoculated with Formalin-killed promastigotes, with or without glucan (Fig. 1) . At 60 days after the final immunization, each animal was challenged by intravenous injection of 6.40 x 106 amastigotes, and the subsequent amounts of hepatic and splenic parasites were monitored. At 1 h after injection of the amastigotes, hepatic parasite counts were not significantly different for all groups (Fig. 3) (Fig. 4) . By day 10 (Fig. 4) 3 . Proliferation of hepatic parasites on designated days after challenge after an intravenous inoculation of viable amastigotes into untreated control animals (U). killed-parasite treated animals (A), glucan treated animals (0). and glucan-killed parasitetreated animals (0). Values are expressed as the mean ± standard error of the mean. spleen cells, and these animals usually succumb to the infection (25) . Previous attempts at immunization against different forms of leishmaniasis in this highly susceptible animal model have yielded mostly marginal or negative results. Injection of small numbers of virulent L. donovani elicits a relative degree of resistance to subsequent challenge with larger numbers of parasites in hamsters (8) . Similar results were obtained in hamsters infected with virulent L. tropica, although progressive development of infection occurs in stimulated but unchallenged hamsters (23) . Additionally Lainson and Bray (16) found that immunization of hamsters with Formalinkilled L. mexicana amastigotes with Freund's adjuvant fails to elicit resistance against challenge with that parasite.
Our experiments provide the first evidence of enhanced nonspecific resistance of hamsters against visceral leishmaniasis. Glucan administration markedly attenuated the course of L.
dono'ani infection, as evidenced by reduced proliferation of amastigotes in both liver and (2) . Possible lymphokine involvement in glucan-induced leishmanicidal activity merits special future consideration, particularly in mice which exhibit prolonged immunity to the parasite after conjoint glucan-killed parasite treatment (13) .
The response of the hamster to glucan was unique with regard to the absence of measurable glucan-induced splenomegaly or hepatomegaly when compared with reactions of mice or rats given similar glucan doses (6; C. F. Way, Ph.D. thesis, Medical University of South Carolina, Charleston, 1981). These findings suggest that hamsters may have a relatively reduced capacity to recruit monocytes in response to inflammatory stimuli, which may be relevant to their increased vulnerability to leishmanial infections. Nevertheless, granulomatous foci and hypertrophic Kupffer cells with recognizable glucan vacuoles were present in the livers of glucan-treated hamsters, and such a response was associated with reduced numbers of intracellular parasites.
Our results with glucan as an adjuvant in combination with killed promastigotes do not allow us to determine whether the increased resistance was due to glucan potentiation of specific immunity against L. donovani. Such an effect may have been partially masked by the unanticipated degree of protection afforded by glucan alone at challenge 60 days after immunization. Relative to the glucan-treated control group, hamsters receiving glucan-killed promastigote inoculations exhibited highly significant reduction of splenic parasite burdens on days 10 and 21 postinfection. Likewise, this was the only group which exhibited significantly prolonged mean survival time relative to animals not treated before infection. By day 35, however, amastigotes in splenic tissue of the immunized group did not vary significantly from the glucan-treated or parasite-treated control group. These observations suggest that before day 10 postinfection, either fewer parasites failed to initiate infection after challenge of the immunized group or there was enhanced killing or suppression of amastigote proliferation during the early course of the infection. We are presently directing attention to in vitro measures of specific immune responsiveness to clarify these possibilities. (4, 16, 17, 20, 21) .
Glucan as an adjuvant may be more advantageous than certain bacterial adjuvants such as BCG, C. parvum, or Bordetella pertussis. The microbial agents have several disadvantages relating to their bacterial nature, antigenic qualities, difficulty of standardization, possible infectious complications, unknown metabolites, and the fact that the immunostimulant is, in most cases, an unknown entity (6) . In comparison, glucan is nonviable and chemically defined and in limited clinical trials appears to be relatively nontoxic (6, 18) .
In addition to enhancing nonspecific resistance of hamsters and mice to L. donovani infections (3) , glucan increases host resistance to a variety of other infectious agents, including viruses (22, 30) , bacteria (15) , fungi (29) , and protozoa (14) . When used as an adjuvant with killed promastigotes, glucan potentiated immunity of mice against L. donovani infections when challenged several weeks after immunization (13) . Glucan was likewise effective in enhancing the immunogenicity of killed erythrocytic-stage Plasmodium berghei, as determined by an increased proportion of mice surviving after infection with this protozoan (14) . In addition, Reynolds et al. (22) demonstrated that glucan was more effective than Fruend's complete adjuvant in eliciting resistance of mice against Venezuelan equine encephalitis virus (22) . Similarly, injection of the vaccine for that virus in combination with glucan produced a greater antibody response in monkeys than did immunization with the vaccine alone (22) .
These observations, coupled with these studies, which demonstrate that glucan alone or with antigen enhanced resistance against L. donovani in the highly vulnerable hamster, make glucan particularly attractive as an immunotherapeutic agent and as a potential adjuvant in immunoprophylactic trials. The mechanism whereby glucan enhances host resistance to visceral leishmaniasis and the potential use of glucan immunotherapy against severe infectious diseases, including severe forms of leishmaniasis, merits further evaluation.
